PROVECTUS BIOPHARMACEUTICALS, INC. — Operating Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1a0f9045-1753-40a0-b1a3-9eb72472d9ed/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-5.3M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-012726 |
| FY 2024 | $-4.5M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-000993 |
| FY 2023 | $-2.9M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011699 |
| FY 2022 | $-3.4M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-009563 |
| FY 2021 | $-4.7M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-008016 |
| FY 2020 | $-5.0M | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-005194 |
| FY 2019 | $-6.3M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-003433 |
| FY 2018 | $-8.1M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-002987 |
| FY 2017 | $-13.3M | 2017-01-01 – 2017-12-31 | evidence 0001493152-19-002987 |
| FY 2016 | $-24.5M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-106543 |
| FY 2015 | $-24.7M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-523701 |
| FY 2014 | $-12.7M | 2014-01-01 – 2014-12-31 | evidence 0001193125-16-523701 |
| FY 2013 | $-133.5M | 2002-01-18 – 2014-03-31 | evidence 0001193125-14-188810 |
| FY 2012 | $-119.3M | 2002-01-18 – 2013-03-31 | evidence 0001193125-13-211517 |
| FY 2011 | $-105.9M | 2002-01-16 – 2012-03-31 | evidence 0001193125-12-221968 |
| FY 2010 | $-20.7M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-114821 |
| FY 2009 | $-12.3M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-114821 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
PROVECTUS BIOPHARMACEUTICALS, INC. — all facts · Revenue · Net Income